Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albumin-bound docetaxel - CSPC ZhongQi Pharmaceutical Technology

Next Previous
Search
Drug Profile

Albumin-bound docetaxel - CSPC ZhongQi Pharmaceutical Technology

Alternative Names: CPO-100; Docetaxel albumin-bound; Docetaxel for injection (albumin-bound); Docetaxel nanoparticle formulated with human albumin - CSPC ZhongQi Pharmaceutical Technology; DTX-HSA; HB-1801

Latest Information Update: 31 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Developer Conjupro Biotherapeutics; CSPC ZhongQi Pharmaceutical Technology
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastric cancer
  • Phase II Adenocarcinoma; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Phase I/II Squamous cell cancer
  • Phase I Solid tumours

Most Recent Events

  • 27 Dec 2024 Shanghai JMT-Bio plans a phase III trial for Breast cancer (Late-stage disease, Neoadjuvant therapy, in December 2024 (NCT06747338)
  • 31 Jul 2024 CSPC ZhongQi Pharmaceutical Technology plans a phase II trial for Non small cell lung cancer (Late stage disease, Metastatic disease, Recurrent, Unresectable/Inoperable) (Parenteral) in July 2024 (NCT06525350)
  • 09 Jul 2024 CSPC ZhongQi Pharmaceutical Technology plans a phase III trial for Pancreatic cancer (Second-line therapy or greater, Late-stage disease) (IV, Infusion) in August 2024 (NCT06492941)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top